Abstract
Antigen-presenting cells (APCs) integrate signals emanating from local pathology and program appropriate T cell responses. In allogeneic hematopoietic stem cell transplantation (alloHCT), recipient conditioning releases damage-associated molecular patterns (DAMPs) that generate proinflammatory APCs that secrete IL-12, which is a driver of donor Th1 responses, causing graft-versus-host disease (GVHD). Nevertheless, other mechanisms exist to initiate alloreactive T cell responses, as recipients with disrupted DAMP signaling or lacking IL-12 develop GVHD. We established that tissue damage signals are perceived directly by donor CD4+ T cells and promoted T cell expansion and differentiation. Specifically, the fibroblastic reticular cell–derived DAMP IL-33 is increased by recipient conditioning and is critical for the initial activation, proliferation, and differentiation of alloreactive Th1 cells. IL-33 stimulation of CD4+ T cells was not required for lymphopenia-induced expansion, however. IL-33 promoted IL-12–independent expression of Tbet and generation of Th1 cells that infiltrated GVHD target tissues. Mechanistically, IL-33 augmented CD4+ T cell TCR-associated signaling pathways in response to alloantigen. This enhanced T cell expansion and Th1 polarization, but inhibited the expression of regulatory molecules such as IL-10 and Foxp3. These data establish an unappreciated role for IL-33 as a costimulatory signal for donor Th1 generation after alloHCT.
Original language | English (US) |
---|---|
Article number | e150927 |
Journal | Journal of Clinical Investigation |
Volume | 132 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2022 |
Bibliographical note
Funding Information:Conflict of interest: BRB receives remuneration as an advisor to Magenta Therapeutics and BlueRock Therapeutics; receives research funding from BlueRock Therapeutics, Rheos Medicines, and the Childrens’ Cancer Research Fund; and is a cofounder of Tmunity Therapeutics. HRT receives renumeration as a scientific advisor to Slate Biotech and research funding from ECM Therapeutics. WS is a cofounder of, equity holder in, and paid consultant for Bluesphere Bio. Copyright: © 2022, Dwyer et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Submitted: April 29, 2021; Accepted: April 28, 2022; Published: June 15, 2022. Reference information: J Clin Invest. 2022;132(12):e150927. https://doi.org/10.1172/JCI150927.
Funding Information:
We acknowledge the excellent manuscript preparation by Car-la Forsythe and the technical support of Leonardo Scarpelli-no. This project used the University of Pittsburgh Genomics Research Core RNA Analysis services and Division of Laboratory Animal Resources. This work was supported by the following NIH grants: R01AR073527, R01HL22489, and R56AI139327 (to HRT); R37AI34495, R01HL56067, and R01HL11879 (to BRB); and T32CA082084 and F30AI147437 (to GKD). This work benefitted from NIH shared instrumentation grants (S10OD011925 and S10OD023402).
Publisher Copyright:
Copyright: © 2022, Dwyer et al.